The short answer
Reported interactions with growth-factor signalling form part of BPC-157's multi-pathway description, including effects related to growth hormone receptor expression in tendon fibroblast work. Without an identified receptor for the peptide itself, these remain observations rather than a mapped mechanism.
Key facts
- Reported
- Effects on growth-factor signalling
- Context
- Tendon fibroblast and repair models
- Peptide receptor
- None identified
- Interpretation
- Downstream observation, not initiating event
- Evidence type
- In vitro and rodent
- Independent replication
- Limited
What is reported
Work in tendon fibroblast systems has reported effects related to growth hormone receptor expression, and the broader literature describes interactions with growth-factor signalling more generally. These sit within the multi-pathway framing rather than constituting a separate mechanism.
The interpretive problem
An effect on growth-factor signalling can be an initiating event or a downstream consequence of something else entirely. Distinguishing them requires knowing where the compound acts first, and no receptor for BPC-157 has been identified. Without that anchor, a reported change in a signalling pathway is a position in a chain of unknown length rather than a starting point.
Research material referenced
BPC-157 5mg, third-party HPLC tested
Why this recurs across the category
It is the same limitation described in the mechanism article, appearing again in a specific context. Every mechanistic finding for BPC-157 has the same shape: a measurable effect on a known pathway, with no established route from the peptide to that pathway. The findings accumulate without converging.
How growth-factor claims should be read
Growth-factor language carries strong connotations of tissue building and repair, and it is easy for a reported interaction to be presented as a demonstrated growth effect. The reported observations concern signalling components in model systems. They are not evidence of growth, repair or regeneration in an organism.
What would change the picture
A molecular target for the peptide. That would convert every downstream observation from a floating association into a position in a defined pathway, and would make the growth-factor findings interpretable. It remains the single most valuable missing piece in this compound's characterisation.
Frequently asked questions
Does BPC-157 act on growth hormone receptors?
Effects related to growth hormone receptor expression have been reported in tendon fibroblast work. Whether that is an initiating event or downstream of something else is not established.
Why is the absence of a receptor such a problem?
Without knowing where the compound acts first, any downstream finding is a position in a chain of unknown length rather than a mechanism.
Does this mean BPC-157 promotes growth?
No. The observations concern signalling components in model systems, not growth or repair in an organism.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedKrivic A et al., Achilles detachment in rat and BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 Studied Effects, Sorted by EvidenceGastrointestinal, tendon, ligament and vascular models, plus clinical development as PL-14736 and a Phase 2 recruiting now. Ranked by how well established.
- BPC-157 Side Effects and the Absence of Human DataNo controlled human safety study exists. What the rodent literature reports, the theoretical concern that follows from its own mechanism, and what nobody knows.
- What BPC-157 Is Claimed to Do, and in Which SpeciesTendon, ligament, gut and vascular findings - almost entirely in rats. What has been demonstrated, in which species, and why no human timeline exists.
- Is BPC-157 Legal?Not a controlled substance, and not a licensed medicine either. What that gap means, plus the FDA compounding decision and its prohibited status in sport.
- Why BPC-157 and TB-500 Are Called the Wolverine StackAn informal name for combining two repair-studied peptides, after the comic character who heals fast. What the name promises and what the literature supports.